• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Diabetes, Metabolic Syndrome and Cardiovascular Disease 2014 - Product Image

Diabetes, Metabolic Syndrome and Cardiovascular Disease 2014

  • ID: 3037907
  • November 2014
  • Region: Global
  • 266 Pages
  • TriMark Publications
-the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes

FEATURED COMPANIES

  • A. Menarini
  • Biodel
  • Debiotech
  • Insuline Medical Ltd.
  • Novo Nordisk
  • Smiths Medical
  • MORE

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world.

To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold.

Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World READ MORE >

-the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes

FEATURED COMPANIES

  • A. Menarini
  • Biodel
  • Debiotech
  • Insuline Medical Ltd.
  • Novo Nordisk
  • Smiths Medical
  • MORE

1. Overview
1.1 Statement of Report
1.2 About this Report
1.3 Scope of the Report
1.4 Methodology
1.5 Executive Summary

2. Introduction
2.1 Demographics of Diabetes
2.1.1 Worldwide Diabetes
2.1.2 U.S. Diabetes
2.2 Economics of Diabetes
2.2.1 Worldwide Costs of Diabetes
2.2.2 Costs of Diabetes in the U.S.

3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes
3.1 Pre-Diabetes Syndrome
3.2 Metabolic Syndrome
3.2.1 Prevalence of Metabolic Syndrome
3.2.2 Management of Metabolic Syndrome
3.2.3 The Outlook for Metabolic Syndrome
3.2.4 The Debate Regarding Metabolic Syndrome
3.3 Diabetes and Inflammation
3.4 Diagnosis of Diabetes Mellitus
3.5 Progression of Diabetes
3.6 Risk Factors and Diabetes
3.6.1 Obesity
3.6.2 Stress-Induced Hyperglycemia
3.7 Complications and Co-Morbidities in Type 2 Diabetes
3.7.1 Preventing Complications and Co-Morbidities in Diabetes
3.7.2 Hypoglycemia Resulting from Treatment
3.8 Cardiovascular Disease (CVD)
3.8.1 CVD Facts
3.8.2 Cardiac Care Therapeutics
3.8.2.1 Anti-Hypertensive Drugs
3.8.2.2 Cholesterol Management Drugs
3.8.2.3 Anticoagulants
3.8.3 CVD Diagnostics

4. Pharmaceutical Industry and the Anti-Diabetes Market
4.1 The Worldwide Pharmaceutical Industry
4.1.1 Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure
4.1.2 Global Pharmaceutical Market
4.2 Total Diabetes Drug Market Size and Growth
4.2.1 Sales Forecast for the Global Anti-Diabetes Drug Market
4.3 Diabetic Medications Overview
4.3.1 Recent Trends in Diabetic Drug Usage
4.3.2 Market Influence Factors

5. Non-Insulin Anti-Diabetes Products
5.1 Anti-Diabetic Drug Therapy Overview
5.1.1 Sulfonylureas
5.1.2 Meglitinides
5.1.3 Biguanides
5.1.4 Thiazolidinediones (TZDs)
5.1.5 a-Glucosidase Inhibitors
5.1.6 Amylin Analog
5.1.7 Glucagon-like Peptide (GLP-1) Analogs and Agonists/Incretin Mimetics
5.1.7.1 Byetta (Exenatide)
5.1.7.2 Bydureon (Exenatide LAR)
5.1.7.3 Victoza (Liraglutide)
5.1.7.4 Tanzeum (Albiglutide)
5.1.7.5 Trulicity (Dulaglutide)
5.1.8 DPP-IV Inhibitors
5.1.8.1 Januvia (Sitagliptin)
5.1.8.2 Onglyza (Saxagliptin)
5.1.8.3 Tradjenta (Linagliptin)
5.1.8.4 Galvus (Vildagliptin)
5.1.8.5 Nesina (Alogliptin)
5.1.9 SGLT-2 Inhibitors
5.1.9.1 Invokana (Canagliflozin)
5.1.9.2 Farxiga (Dapagliflozin)
5.1.9.3 Jardiance (Empagliflozin)
5.1.9.4 Suglat (Ipragliflozin)
5.1.9.5 Lusefi (Luseogliflozin)
5.1.10 Combination Therapy
5.1.10.1 Antidiabetic Drug Options for Youth with Recent-Onset Type 2 Diabetes Scarce
5.1.11 Comparisons of the Anti-Diabetes Drugs
5.2 Market Drivers and Trends
5.2.1 Market Share and Forecast of Non-Insulin Anti-Diabetic Drugs
5.3 Non-Insulin Anti-Diabetes Products in the Pipeline
5.3.1 Novel GLP-1 Agonists and Analogs
5.3.2 Novel DPP-IV Inhibitors
5.3.3 Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors
5.3.4 Emerging Anti-Diabetes Targets and Drugs in the Pipeline
5.3.4.1 Novel Approaches to Finding New Drug Targets

6. Insulin
6.1 Insulin Markets
6.1.1 Major Players and Market Share
6.1.2 Patent Expirations
6.1.3 Pathway for Insulin Biosimilars
6.1.3.1 Regulatory Avenues for Biosimilar Approval
6.1.3.2 Lantus Biosimilars
6.1.3.3 Key Issues for Insulin Biosimilars
6.1.4 Innovation Strategies
6.2 Insulin Therapeutics
6.2.1 Recommendations for Insulin Initiation and Administration
6.2.2 Short-Acting Insulin
6.2.3 Rapid-Acting Insulin
6.2.3.1 Fast-Acting Insulins in Development
6.2.4 Intermediate-Acting Insulin
6.2.5 Long-Acting Insulin
6.2.6 Insulin Mixtures
6.3 Pipeline Insulins in Development
6.3.1 Tresiba (Novo Nordisk)
6.3.2 Ryzodeg (Novo Nordisk)
6.3.3 Toujeo (Sanofi)
6.3.4 BIOD-531 (Biodel)
6.3.5 Xultophy (Novo Nordisk)
6.3.6 LixiLan (Sanofi)
6.3.7 rHUPH20 and Insulin (Halozyme)
6.3.8 FIAsp (Novo Nordisk)
6.3.9 BIOD-238, BIOD-250, and BIOD-351 (Biodel)
6.3.10 InsuPatch and InsuPad (Insuline Medical)
6.4 Non-Invasive Insulin Delivery
6.4.1 Inhaled Insulin
6.4.1.1 Afrezza
6.4.1.2 Dance Pharmaceuticals and Aerogen (Dance-501)
6.4.1.3 A Chronicle of Inhaled Insulins
6.4.2 Oral Insulin
6.4.3 Transdermal Insulin
6.5 Barriers for Non-Injected Insulin
6.6 Patient Potential for Non-Injected Insulin
6.7 Insulin Delivery Devices
6.7.1 Insulin Pens
6.7.2 Injections Aids
6.7.2.1 Automatic Injectors
6.7.2.2 Syringe Magnifiers
6.7.2.3 Injection Ports
6.7.3 Insulin Jet Injectors
6.7.4 Insulin Pumps
6.7.4.1 External Insulin Pumps
6.7.4.2 OneTouch Ping
6.7.4.3 Accu-Chek Combo Insulin Pump System
6.7.4.4 MiniMed Paradigm Real-Time Revel
6.7.4.5 MiniMed 530G with Enlite
6.7.4.6 Insulet Omnipod
6.7.4.7 DANA IIS
6.7.4.8 t:slim (Tandem Diabetes Care)
6.7.4.9 Snap (Asante)
6.7.4.10 Animas Vibe Pump/CGM
6.7.5 Insulin Infusion Sets
6.7.6 Insulin Patch Pumps in Development or Only Available Outside the U.S.
6.7.7 Implantable Insulin Pumps
6.7.8 Insulin Pump Market Share
6.7.9 Drivers of Demand for Pumps
6.8 Market Forecasts for Insulin Administration Technologies

7. Emerging Anti-Diabetes Technologies and Products
7.1 Projections for the Anti-Diabetes Drug Market
7.2 Artificial Pancreas
7.2.1 MiniMed 530G System
7.2.2 Animas Vibe System
7.2.3 Next Generation Medtronic Artificial Pancreas Systems
7.2.4 FDA’s Artificial Pancreas Guidance Document
7.3 Insulin-Producing Cells
7.3.1 Gene Therapy
7.3.2 Cell Therapy Companies for Diabetes
7.3.2.1 ViaCyte (formerly Novocell, Inc.)
7.3.2.2 Sernova
7.4 Pancreatic Transplantation
7.4.1 Candidates for Pancreatic Transplantation
7.4.1.1 Pancreatic Organ Transplantation
7.4.1.2 Allo-Islet Transplantation
7.4.1.3 Implantation of Genetically Engineered b-Cells or Embryonic Stem Cells
7.4.2 ADA Position on Pancreatic Transplantation
7.5 Immune Modulators
7.6 Gastric Bypass Surgery to Treat Type 2 Diabetes
7.7 Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes
7.7.1 Xenical (Roche)
7.7.2 Qsymia (Vivus)
7.7.3 Belviq (Arena Pharmaceuticals)
7.7.4 Contrave (Orexigen Therapeutics)
7.7.5 Anti-Obesity Drugs in Development
7.8 Other Anti-Diabetic Therapy Drug Candidates
7.8.1 Lipid Abnormalities
7.8.1.1 New Cholesterol Guidelines
7.8.2 High Blood Pressure
7.8.3 Aspirin Therapy
7.9 Drugs Used “Off-Label”
7.9.1 Warfarin Sodium
7.10 Insulin and Anti-Diabetes Drug Combinations
7.10.1 Xultophy (Novo Nordisk)
7.10.2 LixiLan (Sanofi)

8. Diagnosing Diabetes Using In Vitro Laboratory Tests
8.1 Diagnostic Guidelines
8.2 Diagnosis of Diabetes
8.2.1 Fasting Plasma Glucose (FPG) Test
8.2.2 Glucose Tolerance Test
8.2.3 Test for Glycosylated Hemoglobin (HbA1c or A1c)
8.2.4 Fructosamine
8.2.5 Screening Tests for Diabetes-Related Complications
8.3 Glucose Monitoring
8.3.1 Overview of Market Segment
8.3.2 Competitive Strategies
8.3.3 Analyses of the Current Market Conditions, Competition and Product Mix
8.3.3.1 First-Generation Monitors
8.3.3.2 Second-Generation Monitors
8.3.3.3 Third-Generation SMBG Technologies
8.3.3.4 Product Overview
8.3.3.4.1 LifeScan, Inc.
8.3.3.4.2 Roche Diagnostics
8.3.3.4.3 Bayer HealthCare
8.3.3.4.4 Abbott Diabetes Care
8.3.3.4.5 Other Players
8.3.4 What are the Advantages of Using a Continuous Glucose-Monitoring Device?
8.3.5 Minimally-Invasive Continuous Glucose Monitors in Development
8.3.6 Future of Non-Invasive Glucose Technology
8.3.7 Lancets and Lancing Devices

9. Market Trends, Challenges and Strategic Options
9.1 Overview
9.2 Diabetes Drug Market Trends
9.2.1 Overview
9.2.2 Emergence of Therapeutics with Improved Administration Characteristics
9.2.2.1 Barriers to the Initiation of Insulin Therapy in Type 2 Diabetics
9.2.3 Increasing Prevalence of Obesity
9.2.4 Consumer Preference Drives Product Development in Invasive Technology Segment
9.3 Diabetes Mellitus Market Challenges
9.3.1 Overview
9.3.2 Patent Expirations
9.3.3 Market Prospects of Inhalable Insulin
9.4 Strategic Options
9.4.1 Developing Countries are Key Markets for Growth
9.4.2 Consumer-Driven Marketing Campaigns
9.4.3 Strategies for Successful New Product Launches
9.4.4 Collaborations and Strategic Alliances
9.5 FDA Guidelines for Developing Anti-Diabetic Drugs
9.6 Recent Industry Activity

10. Company Profiles
10.1 A. Menarini
10.2 Abbott Laboratories
10.3 Abbvie
10.4 Amgen
10.5 Amylin Pharmaceuticals (bought by Bristol-Myers Squibb)
10.6 Animas (part of Johnson & Johnson)
10.7 Asante
10.8 Astellas Pharma, Inc.
10.9 AstraZeneca Plc
10.10 Bayer
10.11 Becton, Dickinson and Company
10.12 Biocon
10.13 Biodel
10.14 BodyMedia
10.15 Boehringer Ingelheim
10.16 Bristol Myers Squibb
10.17 Cellnovo
10.18 CeQur
10.19 ConjuChem
10.20 Daiichi Sankyo
10.21 Dance Biopharm
10.22 Debiotech
10.23 DexCom
10.24 Echo Therapeutics, Inc.
10.25 Eli Lilly
10.26 FIFTY50 Medical, Inc.
10.27 Flamel Technologies
10.28 Generex Biotechnology Corporation
10.29 GlaxoSmithKline Plc
10.30 Halozyme Therapeutics
10.31 Insulet
10.32 Insuline Medical Ltd.
10.33 Intarcia Therapeutics, Inc.
10.34 Janssen Research & Development
10.35 Johnson & Johnson
10.36 Kowa Pharmaceuticals
10.37 Lexicon Pharmaceuticals
10.38 MannKind Corporation
10.39 Medipacs
10.40 Medtronic
10.41 Merck & Company, Inc.
10.42 Mitsubishi Tanabe Pharma Corporation
10.43 Novartis
10.44 Novo Nordisk
10.45 Oramed Pharmaceuticals
10.46 Orexigen Therapeutics, Inc.
10.47 Owen Mumford
10.48 PhaseBio Pharmaceuticals
10.49 Pfizer
10.50 Prometheon Pharma
10.51 Roche Diagnostics
10.52 Sanofi-Aventis
10.53 Sernova
10.54 Smiths Medical
10.55 SOOIL Development
10.56 Taisho Pharmaceuticals
10.57 Takeda
10.58 Tandem Diabetes Care, Inc.
10.59 Theracos, Inc.
10.60 Transdermal Specialties, Inc.
10.61 TransTech Pharma
10.62 Valeritas
10.63 Viacyte, Inc. (formerly Novocell)
10.64 Vivus, Inc.
10.65 Ypsomed Holding
10.66 Zealand Pharma A/S

Appendix 1: The History of Insulin

LIST OF FIGURES:

Figure 2.1: Worldwide Diabetes Cases, 2013 and 2035
Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013
Figure 2.3: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years, 1980-2012
Figure 2.4: New Adult Cases of Diabetes Diagnosed in the U.S., 2012
Figure 2.5: Diagnosed and Undiagnosed Diabetes by Age in the U.S., 2013
Figure 2.6: Number of Deaths from Diabetes by Age in the U.S., 2010
Figure 2.7: Number of Diabetes Deaths by Race and Sex in the U.S., 2010
Figure 2.8: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79 Years) with Diabetes (USD), 2013
Figure 2.9: How Diabetes Dollars are Spent in the U.S., 2012
Figure 2.10: Percent of Medical Condition-Specific Expenditures Associated with Diabetes, 2012
Figure 3.1: Maintenance of Normal Blood Sugar Levels
Figure 3.2: Prevalence of Self-Reported Obesity (BMI ³30) Among U.S. Adults, 2012
Figure 3.3: Prevalence of Obesity Among Adults in the U.S., 2009-2010
Figure 3.4: Percentage of Obese Children and Adolescents in the U.S., 2009-2010
Figure 3.5: Trends in Obesity Among Children and Adolescents in the U.S., 1988-2010
Figure 3.6: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Sex, in the U.S., 1997-2011
Figure 3.7: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility Limitation, by Age, in the U.S., 1997-2011
Figure 3.8: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed Diabetes Reporting Visual Impairment, in the U.S., 1997-2011
Figure 3.9: Annual Death Rate of U.S. Population from Heart Disease, 1950-2009
Figure 3.10: Annual Death Rate of U.S. Population from Strokes, 1950-2009
Figure 3.11: Percentage Breakdown of Deaths Attributable to Cardiovascular Disease in the U.S., 2010
Figure 3.12: Death Rates from Cardiovascular Disease by State, 2010
Figure 3.13: Percentage of Obese Adults in the U.S., 1960-2010
Figure 3.14: Percentage of Obese Children and Adolescents in the U.S., 1971-2010
Figure 3.15: Number of Annual Prescriptions for Popular Cholesterol Drugs, 2007-2012
Figure 4.1: Sales Forecast for the Global Diabetes Drug Market, 2010-2018
Figure 4.2: Sales Forecast for the U.S. Diabetes Drug Market, 2010-2018
Figure 4.3: Percentage of U.S. Diabetics Taking Medications, 2010-2012
Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Prescriptions, 2013
Figure 5.1: Overview of GLP-1 and Blood Glucose
Figure 5.2: Overview of DPP-4 Inhibitors and Blood Glucose
Figure 5.3: SGLT-2 Inhibitor Mechanism of Action
Figure 5.4: Global Non-Insulin Anti-Diabetes Sales by Drug Class, 2013
Figure 5.5: Global Non-Insulin Anti-Diabetes Prescriptions by Drug Class, 2013
Figure 6.1: Global Sales of Lantus, 2005-2013
Figure 6.2: Insulin Pump Market Share, 2013

LIST OF TABLES:

Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions, 2013 and 2035
Table 2.2: Top Ten Countries with the Largest Estimated Number of Diabetics (20-79 Years Age Group), 2013 and 2035
Table 2.3: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group, 2013
Table 2.4: Countries with the Largest Number of Deaths Attributable to Diabetes, 2013
Table 2.5: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013
Table 2.6: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010
Table 2.7: Cost of Diagnosed Diabetes in the U.S., 2012
Table 2.8: Annual Cost of Care of United Healthcare Adult Members with Diabetes, 2009
Table 2.9: Healthcare Utilization by Diabetic Patients, 2012
Table 3.1: International Diabetes Federation (IDF) Diagnostic Criteria for Metabolic Syndrome
Table 3.2: Ethnic Specific Values for Waist Circumference in IDF’s Metabolic Syndrome Criteria
Table 3.3: American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) Diagnostic Criteria for Metabolic Syndrome
Table 3.4: Additional Metabolic Criteria for Research
Table 3.5: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.
Table 3.6: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes
Table 3.7: Prevalence of Complications Among Patients with Diabetes
Table 3.8: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
Table 3.9: Major Causes of End-Stage Renal Disease
Table 3.10: Clinical Recommendations for Adults with Diabetes
Table 3.11: Laboratory Assessment of Diabetic Vascular Disease
Table 3.12: Average Years Gained Free of Diabetes-Related Disease with Intensive Management
Table 3.13: Summary of Cardiovascular Diseases (CVDs)
Table 3.14: Death Rate from Cardiovascular Diseases by Country, 2008
Table 3.15: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases and Stroke in the U.S., 2010
Table 3.16: Selected Patent Expirations of Cardiac Care Drugs, 2012-2016
Table 3.17: Worldwide Market for Cardiac Care Therapeutics, 2010-2017
Table 4.1: Global R&D Spending in the Pharmaceutical Industry, 2010-2014
Table 4.2: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2013
Table 4.3: Leading Therapy Classes for R&D, 2014
Table 4.4: Leading Disease Indications for R&D, 2014
Table 4.5: Cost of Clinical Trial Protocol Procedure by Endpoint Type, 2012
Table 4.6: Global Pharmaceutical Sales by Region and Country, 2012 and 2017, and CAGR 2008-2012 and 2013-2017
Table 4.7: World Pharmaceutical Sales Share by Region, 2012
Table 4.8: Leading Ten Therapeutic Classes by U.S. Sales, 2009-2013
Table 4.9: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2009-2013
Table 4.10: Estimated Leading Therapy Classes by Global Sales in the Developed Market, 2017
Table 4.11: Estimated Leading Therapy Classes by Global Sales in the Pharmerging Market, 2017
Table 4.12: Top Selling Drugs in the U.S., 2013
Table 4.13: Top Selling Drugs Worldwide, 2013
Table 4.14: Top Ten Global Pharmaceutical Companies by Global Sales, 2013
Table 4.15: Worldwide Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2010-2018
Table 4.16: U.S. Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2010-2018
Table 4.17: Anti-diabetic Therapy Markets, 2013
Table 4.18: The Leading Five Anti-Diabetics by Global Sales, 2013
Table 4.19: The Leading Five Anti-Diabetics by U.S. Sales, 2013
Table 4.20: Top Five Branded Anti-Diabetics by Prescription in the U.S., 2013
Table 4.21: American College of Physicians 2012 Practical Guideline for the Use of Anti-Diabetes Drugs for Type 2 Diabetes
Table 4.22: Summary of Glucose-Lowering Interventions as Monotherapy
Table 5.1: Classes of Non-Insulin Hypoglycemic Agents
Table 5.2: Branded Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes in the U.S., 2014
Table 5.3: Relative Efficacy of Diabetes Drugs
Table 5.4: Fixed-Dose Oral Anti-Diabetes Drug Combinations
Table 5.5: Worldwide Anti-Diabetes Non-Insulin Drug Market, 2010-2018
Table 5.6: U.S. Anti-Diabetes Non-Insulin Drug Market, 2010-2018
Table 5.7: GLP-1 Agonist Pipeline: Selected Drugs in Development
Table 5.8: DPP-IV Inhibitor Pipeline: Selected Drugs in Development
Table 5.9: SGLT-2 Inhibitor Pipeline: Selected Drugs in Development
Table 5.10: Fixed-Dose Combination Drugs with SGLT-2 Inhibitor: Selected Drugs in Development
Table 5.11: Summary of Emerging Non-Insulin Anti-Diabetes Drug Categories
Table 6.1: Value Market Shares of Animal, Human and Modern Insulin, 1995-2013
Table 6.2: Worldwide Insulin Market, 2010-2018
Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2013
Table 6.4: U.S. Insulin Market, 2010-2018
Table 6.5: Key Drivers of the Type 2 Diabetes Insulin Market, 2013
Table 6.6: Worldwide Insulin Sales and Value Market Share by Company, 2013
Table 6.7: U.S. Insulin Sales and Value Market Share by Company, 2013
Table 6.8: Insulins on the U.S. Market
Table 6.9: Pharmacokinetics of Therapeutic Insulins on the U.S. Market
Table 6.10: Comparison of Recommendations from Existing Guidelines
Table 6.11: Pharmacokinetics of Short-Acting Insulins
Table 6.12: Pharmacokinetics of Rapid-Acting Insulins
Table 6.13: Pharmacokinetics of Intermediate-Acting Insulins
Table 6.14: Pharmacokinetics of Long-Acting Insulins
Table 6.15: Pharmacokinetics of Insulin Mixtures
Table 6.16: A Comparison of Existing Insulin Delivery Devices
Table 6.17: Insulin Pens
Table 6.18: Estimated Worldwide Demand for Insulin Pens by Volume, 2013-2018
Table 6.19: Injection Aids
Table 6.20: Jet Injectors
Table 6.21: Control Averages by Treatment
Table 6.22: Reduced Risk for Various Diseases When Blood Glucose is Near Normal
Table 6.23: Leading Insulin Pump Manufacturers
Table 6.24: Comparison of Current External Insulin Pumps on the Market
Table 6.25: Insulin Infusion Sets
Table 6.26: Worldwide Insulin Pump Market, 2013-2018
Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies
Table 7.2: Cells of the Pancreas
Table 7.3: Statin Recommendations for Designated Treatment Groups
Table 7.4: Statins Currently Available in the U.S.
Table 7.5: Statin Intensity Chart
Table 7.6: Summary of Non-Statin Cholesterol Lowering Drugs
Table 7.7: Suggested Pharmacological Treatment Agents for Hypertension
Table 8.1: Criteria for the Diagnosis of Diabetes
Table 8.2: Categories of Increased Risk for Diabetes (Pre-Diabetes)
Table 8.3: Normal Glucose Values—Fasting State
Table 8.4: Criteria for Testing for Diabetes in Asymptomatic Adults
Table 8.5: Criteria for Type 2 Diabetes in Asymptomatic Children
Table 8.6: Screening for and Diagnosis of Gestational Diabetes Mellitus (GDM)
Table 8.7: Laboratory Assessment of Diabetic Vascular Disease
Table 8.8: Worldwide Glucose Self-Testing Market Sales (includes Meters, Strips and Lancets), 2012-2018
Table 8.9: Market for Glucose Self-Testing in the U.S. (includes Meters, Strips and Lancets), 2012-2018
Table 8.10: Market Share of U.S. Blood Glucose Self-Testing, 2013
Table 8.11: Lancet Characteristics
Table 9.1: BRIC countries, Percentage of GDP Spent on Healthcare, 2013
Table A1.1: Select Archived Press Release Excerpts

-the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes

- A. Menarini
- Abbott Laboratories
- Abbvie
- Amgen
- Amylin Pharmaceuticals (bought by Bristol-Myers Squibb)
- Animas (part of Johnson & Johnson)
- Asante
- Astellas Pharma, Inc.
- AstraZeneca Plc
- Bayer
- Becton, Dickinson and Company
- Biocon
- Biodel
- BodyMedia
- Boehringer Ingelheim
- Bristol Myers Squibb
- Cellnovo
- CeQur
- ConjuChem
- Daiichi Sankyo
- Dance Biopharm
- Debiotech
- DexCom
- Echo Therapeutics, Inc.
- Eli Lilly
- FIFTY50 Medical, Inc.
- Flamel Technologies
- Generex Biotechnology Corporation
- GlaxoSmithKline Plc
- Halozyme Therapeutics
- Insulet
- Insuline Medical Ltd.
- Intarcia Therapeutics, Inc.
- Janssen Research & Development
- Johnson & Johnson
- Kowa Pharmaceuticals
- Lexicon Pharmaceuticals
- MannKind Corporation
- Medipacs
- Medtronic
- Merck & Company, Inc.
- Mitsubishi Tanabe Pharma Corporation
- Novartis
- Novo Nordisk
- Oramed Pharmaceuticals
- Orexigen Therapeutics, Inc.
- Owen Mumford
- PhaseBio Pharmaceuticals
- Pfizer
- Prometheon Pharma
- Roche Diagnostics
- Sanofi-Aventis
- Sernova
- Smiths Medical
- SOOIL Development
- Taisho Pharmaceuticals
- Takeda
- Tandem Diabetes Care, Inc.
- Theracos, Inc.
- Transdermal Specialties, Inc.
- TransTech Pharma
- Valeritas
- Viacyte, Inc. (formerly Novocell)
- Vivus, Inc.
- Ypsomed Holding
- Zealand Pharma A/S

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos